Evidence map›Paper›PMID 38672668›Full record

ArticleCancers2024

Th2 Cells Are Associated with Tumor Recurrence Following Radiation.

Mohamed K Abdelhakiem, Riyue Bao, Phillip M Pifer, David Molkentine, Jessica Molkentine, Andrew Hefner, Beth Beadle, John V Heymach, Jason J Luke, Robert L Ferris and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Mohamed K AbdelhakiemDepartment of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15232, USA.ORCID 0000-0002-3523-8727
Riyue BaoDepartment of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15232, USA.
Phillip M PiferDepartment of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15232, USA.
David MolkentineDepartment of Thoracic-Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jessica MolkentineDepartment of Thoracic-Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-3757-7167
Andrew HefnerDepartment of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15232, USA.
Beth BeadleDepartment of Radiation Oncology, Stanford University, Stanford, CA 94305, USA.
John V HeymachDepartment of Thoracic-Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jason J LukeDepartment of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15232, USA.ORCID 0000-0002-1182-4908
Robert L FerrisDepartment of Otolaryngology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15232, USA.
Curtis R PickeringDepartment of Surgery-Otolaryngology, Yale University, New Haven, CT 06520, USA.ORCID 0000-0002-7942-728X
Jing H WangDepartment of Medicine, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15232, USA.
Ravi B PatelDepartment of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15232, USA.ORCID 0000-0002-8328-746X
Heath D SkinnerDepartment of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15232, USA.
UPMC Hillman Cancer Center · USThe University of Texas MD Anderson Cancer Center · USStanford University · USYale University · US

Funding

WILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Greg M. Delgoffe · 2004 to 2026
$49.6M
Elucidating Mechanism of Immune Evasion in Head and Neck CancersR01DE027329 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, JING HONG, WANG, XIAO-JING · 2018 to 2022
$2.8M
Synthetic Lethal Targeting of CREBBP/EP300 in Head and Neck Squamous Cell CarcinomaR01DE028061 · NIDCR · YALE UNIVERSITY · PI PICKERING, CURTIS, SKINNER, HEATH DEVIN · 2019 to 2023
$2.8M
Extension of Radiotherapy ResearchR01CA168485 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SKINNER, HEATH DEVIN · 2011 to 2021
$2.8M
Postdoctoral Training in Head and Neck OncologyT32CA060397 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZEVALLOS, JOSE P. · 1994 to 2024
$2.7M
Enhancing immune mediated head and neck cancer anti-tumor activity using nanoparticlesR01DE028105 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KRISHNAN, SUNIL, SKINNER, HEATH DEVIN · 2019 to 2023
$2.4M
Targeting non-canonical p16 signaling to improve radiation response and outcome in head and neck cancerR01DE032337 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Heath Devin Skinner · 2023 to 2026
$2.3M
Mechanistic connection between HPV-specific TCRs and therapeutic responses to ICI in HPV+ HNSCCR01CA282074 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Robert L. Ferris, Jing Hong Wang · 2024 to 2026
$2.0M
Utilization of molecular targeted radionuclides to prime immune responses at local and distant metastatic tumor sitesK08CA241319 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI PATEL, RAVI BHASKER · 2019 to 2023
$629k
NCI NIH HHS K08 CA241319NCI NIH HHS P50 CA097190NCI NIH HHS P50CA097190-15NCI NIH HHS R01CA168485-08NCI NIH HHS R01 CA282074NIDCR NIH HHS R01 DE027329NIDCR NIH HHS R01 DE028061NIDCR NIH HHS R01 DE028105NIDCR NIH HHS R01 DE032337NIH HHS 5T32CA060397-27
6 · The paper itself

Abstract

The curative treatment of multiple solid tumors, including head and neck squamous cell carcinoma (HNSCC), utilizes radiation. The outcomes for HPV/p16-negative HNSCC are significantly worse than HPV/p16-positive tumors, with increased radiation resistance leading to worse locoregional recurrence (LRR) and ultimately death. This study analyzed the relationship between immune function and outcomes following radiation in HPV/p16-negative tumors to identify mechanisms of radiation resistance and prognostic immune biomarkers. A discovery cohort of 94 patients with HNSCC treated uniformly with surgery and adjuvant radiation and a validation cohort of 97 similarly treated patients were utilized. Tumor immune infiltrates were derived from RNAseq gene expression. The immune cell types significantly associated with outcomes in the discovery cohort were examined in the independent validation cohort. A positive association between high Th2 infiltration and LRR was identified in the discovery cohort and validated in the validation cohort. Tumor mutations in CREBBP/EP300 and CASP8 were significantly associated with Th2 infiltration. A pathway analysis of genes correlated with Th2 cells revealed the potential repression of the antitumor immune response and the activation of BRCA1-associated DNA damage repair in multiple cohorts. The Th2 infiltrates were enriched in the HPV/p16-negative HNSCC tumors and associated with LRR and mutations in CASP8, CREBBP/EP300, and pathways previously shown to impact the response to radiation.

Indexed as

biomarkersimmune microenvironmentradiationresistancetumor microenvironment

Identifiers

PMID38672668
PMCPMC11049347
OpenAlexW4395009936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.